Company
NYSE:JNJ
Johnson & Johnson is a diversified healthcare products company. The company is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through two segments: Pharmaceutical and MedTech.
152 stories · page 7 of 8
J&J is paying $280 a share in cash for Actelion, retaining the Swiss firm's commercially available treatments for rare diseases such as pulmonary arterial hypertension.
US shares ended higher on Wednesday, as energy investors shrugged off a jump in US oil stocks, and markets took a sanguine view of President-elect Donald Trump’s first speech since he won the November election
US stocks ended the year on a low point, as the Dow ebbed further away from 20,000 and other tickers also printed sharp declines
On the last full day’s trading before the Christmas holiday, US stocks ended lower on Thursday as markets began to wind down
J&J abruptly bowed out of the bid process for Actelion last week after the Swiss firm said that it was “engaged in discussions with another party”.
Glaxo has developed the new two-drug cocktail through its majority-owned ViiV Healthcare joint venture, in which US firm Pfizer and Japan’s Shionogi also hold stakes.
Johnson & Johnson shares rose on Friday despite a federal court ruling in Dallas on Thursday which ordered the pharma and its DePuy Orthopaedics unit to pay more than $1bn to six Californian plaintiffs who said they were injured by Pinnacle
US stocks snapped back from initial losses to close Wednesday higher and the Dow even managed an intraday record peak, while small-caps had one of their best days in 14 years, after Donald Trump and the Republicans’ sweep into office
The world’s largest healthcare company Johnson & Johnson’s third-quarter earnings per share came in 3 cents higher than analysts’ forecasts. But Pfizer said it will launch a cheaper competing product to J&J's flagship drug Remicade
US stocks ended higher on Tuesday with a boost from high drama in the healthcare sector
Tracon expects to initiate a Phase 1/2 proof-of-concept (POC) clinical trial for one of the molecules, TRC253, in prostate cancer applications in the first half of next year.
Sales and earnings guidance has now been upgraded.
US stocks closed lower on Monday as weaker oil prices, worries over a possible UK Brexit vote and anxieties ahead of the Federal Reserve rate meeting midweek, unsettled the bourse
Signs of stability returning to the battered Chinese economy buoyed markets
Johnson & Johnson first quarter results bode well for the Medtech industry's earnings season, broker Wedbush says
US stocks close higher as oil price gains on the back of signs of stability returning to the battered Chinese economy
In the small cap world, the Russell 2,000, was around seven points higher at 1,146.
Wall Street shares are set for a higher open after a good day yesterday, which saw stocks close at their highest levels of the year.
In the small cap world, the Russell 2,000, was around seven points higher at 1,146.
Drug company boosted 2015 revenues and achieved better-than-expected dip in earnings
